Retraction
Tumor Dependence on the EGFR Signaling Pathway Expressed by the p-EGFR:p-AKT Ratio Predicts Erlotinib Sensitivity in Human Non-small Cell Lung Cancer (NSCLC) Cells Expressing Wild-Type EGFR Gene
Paper Information
Record ID:
36334
Author(s):
Journal:
Publication Date:
June 01, 2008
Retraction Date:
August 16, 2021
(4.3 years years ago)
Subjects:
Institution:
Department of Oncology, Montefiore Medical Center and the Albert Einstein Cancer Center, Bronx, NYCountry:
🇺🇸 United StatesArticle Type:
Publisher:
Elsevier
Open Access:
Yes
PubMed ID:
Retraction PubMed ID:
Not indexed in PubMed
Retraction Details
Retraction Reasons:
Nature of Retraction:
Retraction
Retraction Notice:
10.1097/JTO.0b013e3181753b24Additional Notes:
date of rettrraction unknown, html page overwrite - date taken from date of journal notification as provided;
Citations (20)
20
Total Citations2
Post-Retraction(10.0%)
18
Pre-Retraction0
Same DayPost-Retraction Citation Analysis
0
Within 30 days
2
Within 1 year
0
After 2+ years
138
Days since retraction (latest)
SH003 and Docetaxel Show Synergistic Anticancer Effects by Inhibiting EGFR Activation in Triple-Negative Breast Cancer
Yu‐Jeong Choi, Kangwook Lee, Ji‐Hye Yoon et al. (10 authors)
BioMed Research International
Open Access
Published: Jan 2022
10 citations
10 citations
138 days after retraction
A multifunctional nanotheranostic agent potentiates erlotinib to EGFR wild-type non-small cell lung cancer
Duo Wang, Jun Zhou, Weimin Fang et al. (10 authors)
Bioactive Materials
Open Access
Published: Nov 2021
44 citations
44 citations
80 days after retraction
Single-cell transcriptional changes associated with drug tolerance and response to combination therapies in cancer
Alexandre F. Aissa, Abul Bashar Mir Md. Khademul Islam, Majd Ariss et al. (15 authors)
Nature Communications
Open Access
Published: Mar 2021
195 citations
195 citations
157 days before retraction
LncRNA SOX2‐OT regulates AKT/ERK and SOX2/GLI‐1 expression, hinders therapy, and worsens clinical prognosis in malignant lung diseases
Abril Marcela Herrera‐Solorio, Irlanda Peralta‐Arrieta, Leonel Armas‐López et al. (13 authors)
Molecular Oncology
Open Access
Published: Dec 2020
41 citations
41 citations
251 days before retraction
Mutation and drug-specific intracellular accumulation of EGFR predict clinical responses to tyrosine kinase inhibitors
Maurice de Wit, Ya Gao, Darlene Mercieca et al. (9 authors)
EBioMedicine
Open Access
Published: Jun 2020
12 citations
12 citations
441 days before retraction
Effective Tyrosine Kinase Inhibitors result in the intracellular accumulation of EGFR and allows response prediction in patients
Maurice de Wit, Ya Gao, Darlene Mercieca et al. (9 authors)
bioRxiv (Cold Spring Harbor Laboratory)
Open Access
Published: Oct 2019
665 days before retraction
Retracted Article: MiR-148a agomir based targeting of c-Met and Her-3 is able to attenuate EGFR-T790M mutation driven gefitinib and erlotinib resistance in non-small cell lung cancer cells
Guimin Chen, Lei Ye, Yufei Han et al. (4 authors)
RSC Advances
Open Access
Published: Jan 2019
958 days before retraction
Quantitative Tyrosine Phosphoproteomics of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor-treated Lung Adenocarcinoma Cells Reveals Potential Novel Biomarkers of Therapeutic Response
Xu Zhang, Tapan K. Maity, Manoj Kumar Kashyap et al. (19 authors)
Molecular & Cellular Proteomics
Open Access
Published: Mar 2017
49 citations
49 citations
1607 days before retraction
Long-Term Survival of a Patient With Non–Small-Cell Lung Cancer Harboring a V600E Mutation in the BRAF Oncogene
Nathaniel J. Myall, Joel W. Neal, Cheryl Cho-Phan et al. (8 authors)
Clinical Lung Cancer
Published: Dec 2015
11 citations
11 citations
2067 days before retraction
Shikonin and its derivatives inhibit the epidermal growth factor receptor signaling and synergistically kill glioblastoma cells in combination with erlotinib
Qiaoli Zhao, Nadine Kretschmer, Rudolf Bauer et al. (4 authors)
International Journal of Cancer
Open Access
Published: Feb 2015
75 citations
75 citations
2373 days before retraction
AKT inhibition synergistically enhances growth-inhibitory effects of gefitinib and increases apoptosis in non-small cell lung cancer cell lines
M. Puglisi, P. Thavasu, Andrew N. Stewart et al. (8 authors)
Lung Cancer
Published: Jun 2014
26 citations
26 citations
2632 days before retraction
The Autophagy Inhibitor Chloroquine Overcomes the Innate Resistance of Wild-Type EGFR Non-Small-Cell Lung Cancer Cells to Erlotinib
Yiyu Zou, Yi‐He Ling, Juan Sironi et al. (6 authors)
Journal of Thoracic Oncology
Open Access
Published: Apr 2013
120 citations
120 citations
3049 days before retraction
EGFR-tyrosine kinase inhibitor treatment beyond progression in long-term Caucasian responders to erlotinib in advanced non-small cell lung cancer: A case–control study of overall survival
Martin Faehling, R. Eckert, T. Kamp et al. (8 authors)
Lung Cancer
Published: Mar 2013
43 citations
43 citations
3080 days before retraction
pEGFR-Tyr 845 expression as prognostic factors in oral squamous cell carcinoma
Gabriella Aquino, Giuseppe Pannone, Angela Santoro et al. (21 authors)
Cancer Biology & Therapy
Open Access
Published: Sep 2012
44 citations
44 citations
3271 days before retraction
Mass Spectrometry Mapping of Epidermal Growth Factor Receptor Phosphorylation Related to Oncogenic Mutations and Tyrosine Kinase Inhibitor Sensitivity
Guolin Zhang, Bin Fang, Richard Z. Liu et al. (13 authors)
Journal of Proteome Research
Open Access
Published: Nov 2010
65 citations
65 citations
3926 days before retraction
Correlation Between Epidermal Growth Factor Receptor-Specific Nanobody Uptake and Tumor Burden: A Tool for Noninvasive Monitoring of Tumor Response to Therapy
Lea Olive Tchouate Gainkam, Marleen Keyaerts, Vicky Caveliers et al. (8 authors)
Molecular Imaging and Biology
Published: Sep 2010
58 citations
58 citations
3980 days before retraction
Paper citing Tumor Dependence on the EGFR Signaling Pathway Exp...
Unknown Authors
Unknown Journal
Published: Mar 2009
4537 days before retraction
Retracted: Genistein enhances the effect of epidermal growth factor receptor tyrosine kinase inhibitors and inhibits nuclear factor kappa B in nonsmall cell lung cancer cell lines
Shirish M. Gadgeel, Shadan Ali, Philip A. Philip et al. (5 authors)
Cancer
Open Access
Published: Mar 2009
80 citations
80 citations
4538 days before retraction
Genomic-wide analysis of lymphatic metastasis-associated genes in human hepatocellular carcinoma
Chun-Feng Lee, Zhi Ling, Ting Zhao et al. (7 authors)
World Journal of Gastroenterology
Open Access
Published: Jan 2009
55 citations
55 citations
4610 days before retraction
THE PHARMACOGENOMICS OF EGFR-DEPENDENT NSCLC: PREDICTING AND ENHANCING RESPONSE TO TARGETED EGFR THERAPY
Justin M. Balko
Unknown Journal
Published: Jan 2009
4610 days before retraction
Quick Stats
Total Citations:
20
Years Since Retraction:
4.3 years
Open Access:
Yes
Last Checked:
Jul 24, 2025